Skip to content

EPS (Basic) at other companies

Pfizer logo
PfizerPFE
$0.47-9.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$0.24-167%
Exelixis logo
ExelixisEXEL
$0.81+42.1%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$2.29-103%
Incyte logo
IncyteINCY
$1.52+85.4%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s EPS (basic)?
Nuvalent, Inc. (NUVL) reported EPS (basic) of -$1.39 in Q1 2026.
How has Nuvalent, Inc.'s EPS (basic) changed year-over-year?
Nuvalent, Inc.'s EPS (basic) decreased by 17.8% year-over-year, from -$1.18 to -$1.39.
What is the long-term trend for Nuvalent, Inc.'s EPS (basic)?
Over 3 years (2022 to 2025), Nuvalent, Inc.'s EPS (basic) has grown at a 52.5% compound annual growth rate (CAGR), from -$1.65 to -$5.85.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.